Mitsiades Constantine S, McMillin Douglas W, Klippel Steffen, Hideshima Teru, Chauhan Dharminder, Richardson Paul G, Munshi Nikhil C, Anderson Kenneth C
Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA.
Hematol Oncol Clin North Am. 2007 Dec;21(6):1007-34, vii-viii. doi: 10.1016/j.hoc.2007.08.007.
Multiple myeloma (MM) is viewed as a prototypic disease state for the study of how neoplastic cells interact with their local bone marrow (BM) microenvironment. This interaction reflects not only the osteo-tropic clinical behavior of MM and the clinical impact of the lytic bone lesions caused by its tumor cells but also underlines the broadly accepted notion that nonneoplastic cells of the BM can attenuate the activity of cytotoxic chemotherapy and glucocorticoids. This article summarizes the recent progress in characterization, at the molecular and cellular levels, of how the BM milieu interacts with MM cells and modifies their biologic behavior.
多发性骨髓瘤（MM）被视为研究肿瘤细胞如何与其局部骨髓（BM）微环境相互作用的典型疾病状态。这种相互作用不仅反映了MM的骨嗜性临床行为及其肿瘤细胞引起的溶骨性骨病变的临床影响，还强调了一个广泛接受的观点，即骨髓中的非肿瘤细胞可以减弱细胞毒性化疗和糖皮质激素的活性。本文总结了在分子和细胞水平上，骨髓微环境与MM细胞相互作用并改变其生物学行为的特征方面的最新进展。
